Onesource Specialty Pharma Limited

Onesource Specialty Pharma Limited

Onesource Specialty Pharma Limited has informed the Exchange about Investor Presentation, which can be accessed on their website.

Onesource Specialty Pharma Limited

Onesource Specialty Pharma Limited has informed the Exchange about the dispatch of Notice of the 19th Annual General Meeting (AGM) and Remote e-voting.

Onesource Specialty Pharma Limited

OneSource Specialty Pharma Limited has submitted its Business Responsibility & Sustainability Report (BRSR) for FY26, as required by SEBI regulations.

Onesource Specialty Pharma Limited

Onesource Specialty Pharma Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 23, 2026. The company has also enclosed the Notice of the 19th AGM and the Integrated Annual Report for the financial year 2025-26.

Onesource Specialty Pharma Limited

Onesource Specialty Pharma Limited has informed the Exchange about a scheduled analyst/institutional investor meet on September 03, 2026, at their manufacturing facility in Doddaballapura, Bengaluru Rural District.

Onesource Specialty Pharma Limited

Onesource Specialty Pharma Limited has informed the Exchange about Copy of Newspaper Publication regarding the 19th AGM of the Company.

Onesource Specialty Pharma Limited

Onesource Specialty Pharma Limited has informed the Exchange about Credit Rating upgrade by India Ratings & Research (Ind-Ra) for its bank loan facilities.

Onesource Specialty Pharma Limited

OneSource Specialty Pharma Limited has informed the Exchange about Earnings Call Transcript dated July 25, 2026. The company's CEO and MD, Neeraj Sharma, and CFO, Anurag Bhania, presented the key business and financial highlights for the quarter ended June 30, 2026. Revenues grew 37% year-on-year to INR4,490 million, driven by the semaglutide commercial launch, new MSA contracts, and new customer wins. EBITDA increased 39% year-on-year to INR1,233 million, with a sequential quarter-on-quarter growth of 34%. The company has made significant progress in its sema commercialization in Canada and has launched new products in India.

Onesource Specialty Pharma Limited

OneSource Specialty Pharma Limited has announced a change in management, with Preeti Kalra being designated as a Senior Management Personnel (SMP) and Ravi Kumar resigning as Global Head – Injectables/ Head of Corporate Strategy, Portfolio & SPO, effective July 24, 2026.

Onesource Specialty Pharma Limited

Onesource Specialty Pharma Limited has published un-audited financial results for the quarter ended June 30, 2026, as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Onesource Specialty Pharma Limited

OneSource Specialty Pharma Limited has informed the Exchange about the link of the recording of their earnings call for the unaudited financial results for the quarter ended June 30, 2026. The recording is available on their website.

Onesource Specialty Pharma Limited

Onesource Specialty Pharma Limited has informed the Exchange regarding the allotment of 2,900 Equity Shares under the OneSource Specialty Pharma Limited – Employee Stock Option Plan 2021 to eligible employees upon exercise of vested options. The paid-up share capital of the Company has increased from INR. 11,46,69,991/- to INR. 11,46,72,891/-.

Onesource Specialty Pharma Limited

OneSource Specialty Pharma Limited announced its Q1FY27 results with revenue up 37% YoY and EBITDA up 39% YoY, driven by commercialisation of semaglutide in Canada and India. The company reaffirmed its FY28 guidance of $400 million in organic revenue with 40% EBITDA margin.

Onesource Specialty Pharma Limited

Onesource Specialty Pharma Limited has informed the Exchange about change in Management of the Company, with Preeti Kalra being designated as a Senior Management Personnel and Ravi Kumar resigning from his position.

Onesource Specialty Pharma Limited

OneSource Specialty Pharma Limited has submitted its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, with the auditor's review report stating that nothing has come to their attention that causes them to believe the financial statements contain any material misstatement.

Onesource Specialty Pharma Limited

Onesource Specialty Pharma Limited announced an earnings call scheduled for July 25, 2026 at 10:00 IST to discuss its unaudited financial results for the quarter ended June 30, 2026. The call will be led by CEO & MD Neeraj Sharma and CFO Anurag Bhagania. Dial-in numbers and a DiamondPass link for early registration were provided in the announcement. This is a routine procedural update with no new financial information disclosed.

Onesource Specialty Pharma Limited

OneSource Specialty Pharma Limited has entered into a strategic manufacturing partnership with Formycon AG for biosimilars. The partnership will enable OneSource to provide integrated Drug Substance (DS) and Drug Product (DP) manufacturing capabilities to Formycon. The collaboration aims to expand access to high-quality, affordable biologics for patients worldwide.

Onesource Specialty Pharma Limited

OneSource Specialty Pharma Limited has clarified that the delay in commercial supplies of Semaglutide by Dr. Reddy's Laboratories (DRL) will not have a material impact on their operations, citing sufficient demand from other customers and upcoming capacity additions.

Onesource Specialty Pharma Limited

Onesource Specialty Pharma Limited has informed the Exchange about the allotment of 24,190 equity shares under the OneSource Specialty Pharma Limited – Employee Stock Option Plan 2021 to eligible employees upon exercise of vested options, increasing the paid-up share capital from INR. 11,46,45,801 to INR. 11,46,69,991.

Onesource Specialty Pharma Limited

OneSource Specialty Pharma Limited has informed the Exchange regarding the completion of a US-FDA inspection at its Sterile Product Division facility in Bengaluru, with one observation noted and a comprehensive response to be submitted within the stipulated time frame.